Effects of repaglinide vs glimepiride on serum glucose concentrations, HbA1c and body weight in patients with type 2 diabetes mellitus

Abstract

The present study was designed to compare the efficacy of repaglinide and glimepiride in patients with type 2 DM. The study included 61 type 2 diabetic patients already on metformin therapy (850 mg daily). The primary efficacy end points for comparison were final serum glucose concentrations, and HbA1c and changes in Serum glucose concentrations and HbA1c values from baseline. Repaglinide or glimepiride had been added to metformin in order to control patient’s hyperglycemia. Repaglinide was used in a daily divided dose of 5mg before meals, 2mg at morning, 1mg afternoon, and 2mg at evening. Glimpiride was used in a daily dose of 4mg before lunch. Serum glucose concentrations was measured by using enzymatic colorimetric method and HbA1c was measured by using a commercial kit supplied by STANBIO laboratories, USA.